HealthyPhase 1NCT01272375
This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers
A Phase 1 study testing Treatment A, Treatment B and Treatment C in people with Healthy, run by Pfizer at 1 site in Singapore.
Trial summary
The purpose of this study is to investigate the time course of PF-04764793 concentration in the blood following dosing by oral inhalation from dry powder inhalers. Read more about this study
- Who is it for?
- Ages 21 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Treatment A, Treatment B and Treatment C
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- 1 siteSingapore
- Study dates
- Jan 2011to May 2011
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Healthy male and/or female subjects between the ages of 21 and 55 years.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m^2; and a total body weight >50 kg (110 lbs).
Who cannot join
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- A positive urine drug screen.
- History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males.
- Pregnant or nursing females.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Open Study To Estimate The Plasma Pharmacokinetics Of PF-04764793 Administered Via Oral Inhalation Using Dry Powder Inhalers
The purpose of this study is to investigate the time course of PF-04764793 concentration in the blood following dosing by oral inhalation from dry powder inhalers.
- Conditions
- Healthy
- Being tested
- Treatment A, Treatment B, Treatment C, Treatment D, Treatment E
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Treatment ADrug
PF-04764793 250/50 using inhaler A
Treatment BDrug
PF-04764793 250/50 using inhaler A
Treatment CDrug
PF-04764793 250/50 using inhaler A
Treatment DDrug
PF-04764793 250/50 using inhaler A
Treatment EDrug
PF-04764793 250/50 using inhaler B
Treatment FDrug
PF-04764793 250/50 using inhaler B
Treatment GDrug
PF-04764793 250/50 using inhaler B
| Study group | Role | What they receive |
|---|---|---|
| Treatment A PF-04764793 | Experimental | PF-04764793 using inhaler A Receives: Drug: Treatment A |
| Treatment B PF-04764793 | Experimental | PF-04764793 using inhaler A Receives: Drug: Treatment B |
| Treatment C PF-04764793 | Experimental | PF-04764793 using inhaler A Receives: Drug: Treatment C |
| Treatment D PF-04764793 | Experimental | PF-04764793 using inhaler A Receives: Drug: Treatment D |
| Treatment E PF-04764793 | Experimental | PF-04764793 using inhaler B Receives: Drug: Treatment E |
| Treatment F PF-04764793 | Experimental | PF-04764793 using inhaler B Receives: Drug: Treatment F |
| Treatment G PF-04764793 | Experimental | PF-04764793 using inhaler B Receives: Drug: Treatment G |
What is being measured
The primary outcome is the main question the study is designed to answer.
Plasma pharmacokinetic parameter: Area under the curve (AUClast)from the time of dosing to the last data point taken for PF-04764793
Measured: 48 hours
Plasma pharmacokinetic parameter: Maximum concentration (Cmax) for PF-04764793 in plasma.
Measured: 48 hours
Secondary outcomes (4)
Plasma pharmacokinetic parameter: Area under the curve (AUC0-24) from time of dosing to 24 hours post dose for PF-04764793.
Measured: 48 hours
Plasma pharmacokinetic parameter: Area under the curve (AUCinf) from the time of dosing extrapolated to infinity for PF-04764793.
Measured: 48 hours
Plasma pharmacokinetic parameter: Time of maximum (Tmax) concentration of PF-04764793 in plasma.
Measured: 48 hours
Plasma pharmacokinetic parameter: Terminal half-life of PF-04764793.
Measured: 48 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jan 2011 (estimated)
- Study startJan 2011
- Primary completionMay 2011
- Study completionMay 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01272375
- Sponsor's protocol ID
- B1691011
- Status last verified
- Nov 2018
- First submitted
- 6 Jan 2011
- Last updated
- 3 Dec 2018
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Dec 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open Study To Estimate The Plasma Pharmacokinetics Of PF-04764793 Administered Via Oral Inhalation Using Dry Powder Inhalers
- ClinicalTrials.gov ID
- NCT01272375
- Acronym / sponsor ID
- B1691011
- Conditions
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 48 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Jan 2011
- Primary completion
- May 2011 (actual)
- Study completion
- May 2011 (actual)
- First posted
- 7 Jan 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate the time course of PF-04764793 concentration in the blood following dosing by oral inhalation from dry powder inhalers.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 7
| Arm | Type | Receives |
|---|---|---|
| Treatment A PF-04764793 | Experimental | Drug: Treatment APF-04764793 using inhaler A |
| Treatment B PF-04764793 | Experimental | Drug: Treatment BPF-04764793 using inhaler A |
| Treatment C PF-04764793 | Experimental | Drug: Treatment CPF-04764793 using inhaler A |
| Treatment D PF-04764793 | Experimental | Drug: Treatment DPF-04764793 using inhaler A |
| Treatment E PF-04764793 | Experimental | Drug: Treatment EPF-04764793 using inhaler B |
| Treatment F PF-04764793 | Experimental | Drug: Treatment FPF-04764793 using inhaler B |
| Treatment G PF-04764793 | Experimental | Drug: Treatment GPF-04764793 using inhaler B |
Who may qualify
- Ages
- 21 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Healthy male and/or female subjects between the ages of 21 and 55 years.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m^2; and a total body weight >50 kg (110 lbs).
Key exclusion criteria (4 listed)
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing).
- A positive urine drug screen.
- History of regular alcohol consumption exceeding 14 drinks/week for females or 21 drinks/week for males.
- Pregnant or nursing females.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Treatment APF-04764793 250/50 using inhaler A | Drug | Treatment A PF-04764793 |
| Treatment BPF-04764793 250/50 using inhaler A | Drug | Treatment B PF-04764793 |
| Treatment CPF-04764793 250/50 using inhaler A | Drug | Treatment C PF-04764793 |
| Treatment DPF-04764793 250/50 using inhaler A | Drug | Treatment D PF-04764793 |
| Treatment EPF-04764793 250/50 using inhaler B | Drug | Treatment E PF-04764793 |
| Treatment FPF-04764793 250/50 using inhaler B | Drug | Treatment F PF-04764793 |
| Treatment GPF-04764793 250/50 using inhaler B | Drug | Treatment G PF-04764793 |
Primary outcome
Plasma pharmacokinetic parameter: Area under the curve (AUClast)from the time of dosing to the last data point taken for PF-04764793
Time frame: 48 hours
Plasma pharmacokinetic parameter: Maximum concentration (Cmax) for PF-04764793 in plasma.
Time frame: 48 hours
4 secondary outcomes
Plasma pharmacokinetic parameter: Area under the curve (AUC0-24) from time of dosing to 24 hours post dose for PF-04764793.
Time frame: 48 hours
Plasma pharmacokinetic parameter: Area under the curve (AUCinf) from the time of dosing extrapolated to infinity for PF-04764793.
Time frame: 48 hours
Plasma pharmacokinetic parameter: Time of maximum (Tmax) concentration of PF-04764793 in plasma.
Time frame: 48 hours
Plasma pharmacokinetic parameter: Terminal half-life of PF-04764793.
Time frame: 48 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Dec 2018.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Healthy
RecruitingObservational study
Studies of Blood Flow to the Brain During Thought
Healthy Volunteer
Enrolling by invitationObservational study
Screening for Hematology Branch Protocols
Hematologic Disease and Disorders, Donors
Enrolling by invitationObservational study
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
Neoplasms, Hematologic Neoplasms
Enrolling by invitationObservational study
Collection and Distribution of Samples From Healthy Donors for In Vitro Research at the NCI-Frederick
Healthy Donors
RecruitingObservational study
Collection and Analysis of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers
Healthy Volunteers
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Treatment A, Treatment B and Treatment C in people with Healthy, run by Pfizer at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Plasma pharmacokinetic parameter: Area under the curve (AUClast)from the time of dosing to the last data point taken for PF-04764793 (time frame: 48 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2018; AzTrials last refreshed its copy on 6 Nov 2026.